𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

✍ Scribed by David M. Jackman; Hedy L. Kindler; Beow Y. Yeap; Panos Fidias; Ravi Salgia; Joan Lucca; Linda K. Morse; Patricia A. Ostler; Bruce E. Johnson; Pasi A. Jänne

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
146 KB
Volume
113
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Thrombocytosis in patients with malignan
Thrombocytosis in patients with malignant pleural mesothelioma
✍ Line Lisbeth Olesen; Henning Thorshauge 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB 👁 2 views

Platelet counts were studied retrospectively in a series of 64 patients suspected of primary malignant pleural mesothelioma. Only platelet counts taken before chemotherapy and radiotherapy and surgery other than thoracocentesis were considered. Thirty-two patients had malignant pleural mesothelioma

Cardiac abnormalities in patients with d
Cardiac abnormalities in patients with diffuse malignant pleural mesothelioma
✍ Scott Wadler; Dr. Philippe Chahinian; William Slater; Martin Goldman; David Mend 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 680 KB

Many patients with diffuse malignant pleural mesothelioma have dyspnea or chest pain. Cardiac symptomatology is frequently difficult to differentiate from symptoms of pleuropulmonary disease. To better define the clinical characteristics of cardiac involvement in patients with mesothelioma, the elec

Gemcitabine and vinorelbine in pemetrexe
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
✍ Paolo A. Zucali; Giovanni L. Ceresoli; Isabella Garassino; Fabio De Vincenzo; Ra 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

## Abstract ## BACKGROUND Pemetrexed‐cisplatin chemotherapy is the standard of care in the first‐line treatment of unresectable malignant pleural mesothelioma (MPM). Second‐line cytotoxic therapy is considered for a growing group of patients, but the optimal treatment has not been defined to date.

A phase II study of gemcitabine in patie
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
✍ Jan P. van Meerbeeck; Paul Baas; Channa Debruyne; Harry J. Groen; Chris Manegold 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## BACKGROUND. Gemcitabine has shown activity in patients with less chemosensitive solid tumors. Phase II screening of novel drugs is an accepted method with which to investigate new therapies in malignant mesothelioma. The European Organization for Research and Treatment of Cancer-Lung Cancer Coo

Gemcitabine combined with carboplatin in
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma : A multicentric Phase II study
✍ Adolfo G. Favaretto; Savina M. L. Aversa; Adriano Paccagnella; Vincenzo De Pangh 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract ## BACKGROUND Malignant pleural mesothelioma (MPM) is increasing rapidly worldwide. Currently, pemetrexed plus cisplatin chemotherapy showed a survival advantage versus cisplatin alone. No impact on patient survival of surgery, radiotherapy, or their combination has been demonstrated.